Mereo BioPharma Group (MREO) vs Xilio Therapeutics (XLO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Xilio Therapeutics (XLO) has outperformed Mereo BioPharma Group (MREO) over the past year, losing 22.9% versus a loss of 83.3%. Xilio Therapeutics is the larger company by market cap ($59.6 million vs $55.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MREO | XLO |
|---|---|---|
| Share price | $0.3499 | $9.05 |
| Market cap | $55.88M | $59.55M |
| 1-day change | -6.74% | +0.44% |
| YTD return | -16.09% | +1.00% |
| 1-year return | -83.34% | -22.86% |
| 5-year return | -83.95% | — |
| EPS (TTM) | $-0.18 | $-0.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.37 | $12.59 |
| 52-week low | $0.20 | $6.47 |
| Distance from 52-week high | -85.24% | -28.09% |
| Analyst consensus | none | none |
| Avg. price target upside | +460.16% | +120.99% |
| Average volume | 4.08M | 19.07K |
| Shares outstanding | 159.69M | 6.58M |
| Employees | 39 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XLO has outperformed MREO by 60.5 percentage points over the past year.
About Mereo BioPharma Group
MREO stock →Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2.
Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees
About Xilio Therapeutics
XLO stock →Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
MREO vs XLO FAQ
Which is bigger, Mereo BioPharma Group or Xilio Therapeutics?
Xilio Therapeutics (XLO) is larger, with a market capitalization of $59.55M compared with $55.88M for Mereo BioPharma Group (MREO).
Which stock has performed better over the past year, MREO or XLO?
XLO returned -22.86% over the past 12 months, compared with -83.34% for MREO (price return, excluding dividends). Past performance does not predict future results.
Are Mereo BioPharma Group and Xilio Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.